<DOC>
	<DOCNO>NCT00893451</DOCNO>
	<brief_summary>The purpose study evaluate impact vitamin D3 supplementation insulin resistance non-diabetic patient chronic kidney disease ( CKD ) stag 3-4 , vitamin D deficiency/insufficiency elevate fast serum insulin level .</brief_summary>
	<brief_title>Study Vitamin D3 Supplementation Patients With Chronic Kidney Disease</brief_title>
	<detailed_description>Insulin resistance , i.e. , reduction insulin responsiveness decrease glucose uptake insulin target tissue ( muscle adipose tissue ) common end-stage renal disease ( ESRD ) , also present early stage renal disease mild-moderate renal function impairment well microalbuminuria nephrotic syndrome . Population-based cross-sectional study show low level vitamin D ( 25 ( OH ) vitamin D ) associate impaired glucose tolerance subject normal renal function reduce renal function 25 ( OH ) vitamin D deficiency independently associate insulin resistance . Vitamin D well-known effect calcium metabolism skeletal mineralisation recent experimental study suggest vitamin D addition reduce several inflammatory mediator importance development progression renal disease also associate insulin resistance TNF-α IL-6 . This prospective , single-blind , explorative , randomize , placebo-controlled , single-centre , two-way cross-over study two treatment period 10 week separate washout period 6 week . Non-diabetic patient chronic kidney disease ( CKD ) stage 3 4 ( GFR 15-60 ml/min/1.73m2 ) low serum 25-OH-vitamin D level ( &lt; 30 ng/mL ) elevate fast serum insulin level ( &gt; 10 IU/L ) randomize receive either vitamin D3 ( cholecalciferol ) 3200U orally ( tablet ) daily placebo . Approximately 24 patient go complete study . A pre-entry wash-out period 6 week need patent already vitamin D treatment . An vivo assessment insulin secretion insulin sensitivity make insulin-glucose clamp end treatment period .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Vitamin D Deficiency</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<criteria>1 . Male female , age old 18 year 2 . Nondiabetic chronic kidney disease stage 3 4 ( GFR 1560 ml/min/1.73 m2 ) 3 . Serum 25 ( OH ) vitamin D &lt; 30 ng/mL ( 75 nmol/L ) 4 . Fasting Sinsulin &gt; 30 IU/L 5 . Written inform consent enter study 1 . Patients current significant , major unstable cardiocerebrovascular , infection , respiratory , gastrointestinal major disease risk accord judgment make investigator 2 . Patients type 1 type 2 Diabetes 3 . Current severe thyrotoxicosis endocrine disease 4 . Granulomatous disease , sarcoidosis tuberculosis 5 . Patients intend receive hemodialysis ( HD ) , peritoneal dialysis ( PD ) kidney transplant course study ( 9 month ) 6 . Concomitant use corticosteroid ( except inhalation topical use ) immunosuppressive medication 7 . Treatment biphosphonate last two year 8 . SCalcium &gt; 2.70 mmol/L ( 0.68 mg/dl ) 9 . PTH intact &lt; 75 ng/L ( 8.25 nmol/L ) &gt; 800 ng/L ( 88 nmol/L ) 10 . Proteinuria &gt; 3.5 g/24 hour 11 . Alcohol drug abuse condition associate poor compliance 12 . Blood donor 13 . Women childbearing potential , desired pregnancy , pregnancy lactation within study period 14 . Allergy intolerance cholecalciferol supplementation ( TillVal D® ) constituents 15 . Participation clinical trial evaluate investigational drug last 12 week prior inclusion trial 16 . History kidney stone 17 . History chronic hepatitis liver enzyme ( ASAT ALAT ) 2.5 time upper limit normal 18 . Gastrointestinal disease result significant gastrointestinal dysfunction malabsorption 19 . Use medication know interact vitamin D metabolism cholestyramine , phenytoin , digitalis antacid 20 . Planned vacation `` high sun exposure '' study period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>renal disease</keyword>
	<keyword>renal impairment</keyword>
	<keyword>chronic kidney disease stage 3-4</keyword>
	<keyword>25 ( OH ) vitamin D</keyword>
	<keyword>cholecalciferol</keyword>
	<keyword>vitamin D deficiency</keyword>
	<keyword>insulin resistance</keyword>
	<keyword>insulin-glucose clamp</keyword>
	<keyword>non-diabetic</keyword>
</DOC>